At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 371 enrolled
Drug / intervention
Metformin XRdrug
Likely dose
Metformin XR 500mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Relationship Between Baseline Body Weight and Glycemic Control Following Metformin Extended-Release Tablets (Glucophage XR) Monotherapy in Chinese Patients With Newly Diagnosed Type 2 Diabetes
In Brief
A Phase 4 clinical trial evaluating Metformin XR for Type 2 Diabetes Mellitus. Completed, enrolled 371 participants across 14 sites.
Detailed Summary
The purpose of this study is to investigate the effect of the baseline body mass index (BMI) on the response to Glucophage XR monotherapy in glycemic control in Chinese patients with newly diagnosed type 2 diabetes
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2008
Enrollment StartNov 2009
Primary CompletionMar 2011
TodayJul 2026
First PostedOct 23, 2008
Enrollment StartNov 1, 2009
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 17.7 years ago
Interventions
Metformin XRdrug
Tablets, Oral, 500mg tid, 1500 mg/day, 16 weeks